Header Logo

Connection

JOHN KIRKWOOD to Aged

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Aged.
JOHN KIRKWOOD
Connection Strength
2.340
Aged
  1. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
    View in: PubMed
    Score: 0.067
  2. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.052
  3. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
    View in: PubMed
    Score: 0.047
  4. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
    View in: PubMed
    Score: 0.045
  5. Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
    View in: PubMed
    Score: 0.045
  6. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
    View in: PubMed
    Score: 0.043
  7. Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 10 23; 6(1):112.
    View in: PubMed
    Score: 0.043
  8. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
    View in: PubMed
    Score: 0.043
  9. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
    View in: PubMed
    Score: 0.042
  10. A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. Melanoma Res. 2017 10; 27(5):429-438.
    View in: PubMed
    Score: 0.040
  11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
    View in: PubMed
    Score: 0.040
  12. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.040
  13. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017 Jul 15; 123(14):2688-2697.
    View in: PubMed
    Score: 0.039
  14. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
    View in: PubMed
    Score: 0.038
  15. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015 Sep 30; 13:319.
    View in: PubMed
    Score: 0.035
  16. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
    View in: PubMed
    Score: 0.035
  17. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53.
    View in: PubMed
    Score: 0.033
  18. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
    View in: PubMed
    Score: 0.031
  19. ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.
    View in: PubMed
    Score: 0.031
  20. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013 Aug 01; 19(15):4228-38.
    View in: PubMed
    Score: 0.030
  21. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
    View in: PubMed
    Score: 0.029
  22. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012 Nov-Dec; 35(9):702-10.
    View in: PubMed
    Score: 0.029
  23. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May; 35(4):359-66.
    View in: PubMed
    Score: 0.028
  24. Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J Immunol Methods. 2012 Feb 28; 376(1-2):108-12.
    View in: PubMed
    Score: 0.027
  25. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
    View in: PubMed
    Score: 0.027
  26. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):555-67.
    View in: PubMed
    Score: 0.027
  27. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011 Dec 01; 17(23):7451-61.
    View in: PubMed
    Score: 0.027
  28. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81.
    View in: PubMed
    Score: 0.026
  29. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer. 2011 Sep 06; 105(6):773-7.
    View in: PubMed
    Score: 0.026
  30. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
    View in: PubMed
    Score: 0.026
  31. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
    View in: PubMed
    Score: 0.024
  32. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother. 2010 Apr; 33(3):316-25.
    View in: PubMed
    Score: 0.024
  33. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010 Feb 01; 16(3):1042-8.
    View in: PubMed
    Score: 0.024
  34. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
    View in: PubMed
    Score: 0.022
  35. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15; 15(4):1443-51.
    View in: PubMed
    Score: 0.022
  36. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009 Jan 01; 27(1):38-44.
    View in: PubMed
    Score: 0.022
  37. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
    View in: PubMed
    Score: 0.020
  38. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
    View in: PubMed
    Score: 0.019
  39. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
    View in: PubMed
    Score: 0.018
  40. Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg. 2005; 83(5-6):213-21.
    View in: PubMed
    Score: 0.018
  41. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.018
  42. Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma? Nat Clin Pract Oncol. 2005 May; 2(5):240-1.
    View in: PubMed
    Score: 0.017
  43. Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
    View in: PubMed
    Score: 0.017
  44. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
    View in: PubMed
    Score: 0.017
  45. Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
    View in: PubMed
    Score: 0.017
  46. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
    View in: PubMed
    Score: 0.016
  47. Melanoma in the older person. Oncology (Williston Park). 2004 Aug; 18(9):1187-96; discussion 1196-7.
    View in: PubMed
    Score: 0.016
  48. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. Oncologist. 2024 Jul 05; 29(7):619-628.
    View in: PubMed
    Score: 0.016
  49. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004 Jun; 14(3):217-22.
    View in: PubMed
    Score: 0.016
  50. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
    View in: PubMed
    Score: 0.016
  51. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
    View in: PubMed
    Score: 0.016
  52. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.016
  53. Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. Front Immunol. 2023; 14:1171978.
    View in: PubMed
    Score: 0.015
  54. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
    View in: PubMed
    Score: 0.014
  55. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.014
  56. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 04 30; 399(10336):1718-1729.
    View in: PubMed
    Score: 0.014
  57. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 09 23; 385(13):1196-1206.
    View in: PubMed
    Score: 0.013
  58. Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases. Melanoma Res. 2021 06 01; 31(3):264-267.
    View in: PubMed
    Score: 0.013
  59. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 08 20; 39(24):2656-2666.
    View in: PubMed
    Score: 0.013
  60. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.
    View in: PubMed
    Score: 0.013
  61. Neoadjuvant Pembrolizumab and High-Dose IFNa-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021 08 01; 27(15):4195-4204.
    View in: PubMed
    Score: 0.013
  62. Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. J Extracell Vesicles. 2021 02; 10(4):e12063.
    View in: PubMed
    Score: 0.013
  63. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000 Nov 15; 18(22):3782-93.
    View in: PubMed
    Score: 0.012
  64. Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
    View in: PubMed
    Score: 0.012
  65. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
    View in: PubMed
    Score: 0.012
  66. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
    View in: PubMed
    Score: 0.012
  67. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.012
  68. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-58.
    View in: PubMed
    Score: 0.012
  69. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
    View in: PubMed
    Score: 0.012
  70. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019 09 04; 7(1):239.
    View in: PubMed
    Score: 0.011
  71. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep; 17(9):2745-51.
    View in: PubMed
    Score: 0.011
  72. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 08; 83(2):587-590.
    View in: PubMed
    Score: 0.011
  73. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
    View in: PubMed
    Score: 0.011
  74. PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep. 2019 03 01; 9(1):3309.
    View in: PubMed
    Score: 0.011
  75. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999 Jan; 5(1):11-20.
    View in: PubMed
    Score: 0.011
  76. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.011
  77. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018 06; 28(3):211-221.
    View in: PubMed
    Score: 0.011
  78. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.010
  79. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018 Feb; 25(2):356-377.
    View in: PubMed
    Score: 0.010
  80. Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol. 2018 04; 78(4):701-709.e1.
    View in: PubMed
    Score: 0.010
  81. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2018 02 01; 36(4):391-398.
    View in: PubMed
    Score: 0.010
  82. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
    View in: PubMed
    Score: 0.010
  83. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
    View in: PubMed
    Score: 0.010
  84. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67.
    View in: PubMed
    Score: 0.010
  85. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
    View in: PubMed
    Score: 0.010
  86. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg. 2018 01; 128(1):14-22.
    View in: PubMed
    Score: 0.010
  87. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
    View in: PubMed
    Score: 0.009
  88. Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 1996 Jul; 2(7):1129-34.
    View in: PubMed
    Score: 0.009
  89. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016 Apr 05; 15(1):171-180.
    View in: PubMed
    Score: 0.009
  90. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
    View in: PubMed
    Score: 0.009
  91. Intermediate-grade meningeal melanocytoma associated with nevus of Ota: a case report and review of the literature. Melanoma Res. 2015 Aug; 25(4):273-8.
    View in: PubMed
    Score: 0.009
  92. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
    View in: PubMed
    Score: 0.009
  93. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8.
    View in: PubMed
    Score: 0.008
  94. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
    View in: PubMed
    Score: 0.008
  95. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.008
  96. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32.
    View in: PubMed
    Score: 0.008
  97. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
    View in: PubMed
    Score: 0.007
  98. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer. 2013 Aug 01; 119(15):2737-46.
    View in: PubMed
    Score: 0.007
  99. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22.
    View in: PubMed
    Score: 0.007
  100. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med. 2012 Sep 05; 10:185.
    View in: PubMed
    Score: 0.007
  101. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J Cancer Res Ther. 2012 Apr-Jun; 8(2):215-21.
    View in: PubMed
    Score: 0.007
  102. Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. J Am Acad Dermatol. 1992 Feb; 26(2 Pt 1):185-90.
    View in: PubMed
    Score: 0.007
  103. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012 Feb 15; 18(4):1129-37.
    View in: PubMed
    Score: 0.007
  104. Comparison of nonfamilial and familial melanoma. Dermatology. 1992; 184(1):2-7.
    View in: PubMed
    Score: 0.007
  105. Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer. 1991 Aug; 64(2):373-6.
    View in: PubMed
    Score: 0.007
  106. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16.
    View in: PubMed
    Score: 0.006
  107. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med. 2011 May 26; 9:78.
    View in: PubMed
    Score: 0.006
  108. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011 May 05; 9:52.
    View in: PubMed
    Score: 0.006
  109. A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology. 1991 May; 2(3):210-4.
    View in: PubMed
    Score: 0.006
  110. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Oct; 8(10):1637-49.
    View in: PubMed
    Score: 0.006
  111. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011 Mar; 114(3):769-79.
    View in: PubMed
    Score: 0.006
  112. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.006
  113. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med. 2010 Mar 19; 8:27.
    View in: PubMed
    Score: 0.006
  114. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
    View in: PubMed
    Score: 0.006
  115. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med. 1990 Jan-Feb; 52(1):73-85.
    View in: PubMed
    Score: 0.006
  116. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009 Nov 15; 15(22):7036-44.
    View in: PubMed
    Score: 0.006
  117. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
    View in: PubMed
    Score: 0.006
  118. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 2009 Sep 15; 69(18):7459-65.
    View in: PubMed
    Score: 0.006
  119. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68.
    View in: PubMed
    Score: 0.006
  120. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
    View in: PubMed
    Score: 0.006
  121. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
    View in: PubMed
    Score: 0.005
  122. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5748-54.
    View in: PubMed
    Score: 0.005
  123. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer. 2008 Oct 01; 113(7):1632-40.
    View in: PubMed
    Score: 0.005
  124. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
    View in: PubMed
    Score: 0.005
  125. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3462-9.
    View in: PubMed
    Score: 0.005
  126. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008 May 10; 26(14):2292-8.
    View in: PubMed
    Score: 0.005
  127. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
    View in: PubMed
    Score: 0.005
  128. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 01; 112(5):982-94.
    View in: PubMed
    Score: 0.005
  129. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer. 2008 Mar 01; 112(5):1131-8.
    View in: PubMed
    Score: 0.005
  130. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008 Feb 20; 26(6):955-62.
    View in: PubMed
    Score: 0.005
  131. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6796-806.
    View in: PubMed
    Score: 0.005
  132. A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol. 1987 Nov; 5(11):1804-10.
    View in: PubMed
    Score: 0.005
  133. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007 Sep 01; 25(25):3802-7.
    View in: PubMed
    Score: 0.005
  134. Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol. 1987 Aug; 5(8):1247-55.
    View in: PubMed
    Score: 0.005
  135. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar; 60(3):471-81; discussion 481-2.
    View in: PubMed
    Score: 0.005
  136. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007 Jan; 30(1):75-82.
    View in: PubMed
    Score: 0.005
  137. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007; 54:241-7.
    View in: PubMed
    Score: 0.005
  138. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10; 24(29):4738-45.
    View in: PubMed
    Score: 0.005
  139. Prognostic role of antibody reactivity to melanoma. J Clin Invest. 1986 Apr; 77(4):1116-21.
    View in: PubMed
    Score: 0.005
  140. Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005 Dec 15; 104(12):2784-91.
    View in: PubMed
    Score: 0.004
  141. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec; 123(12):1639-43.
    View in: PubMed
    Score: 0.004
  142. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985 Jul; 103(1):32-6.
    View in: PubMed
    Score: 0.004
  143. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
    View in: PubMed
    Score: 0.004
  144. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
    View in: PubMed
    Score: 0.004
  145. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004 Jun 01; 22(11):2101-7.
    View in: PubMed
    Score: 0.004
  146. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984 Mar; 2(3):164-8.
    View in: PubMed
    Score: 0.004
  147. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003 Dec; 13(6):619-26.
    View in: PubMed
    Score: 0.004
  148. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003 Jul 01; 98(1):100-9.
    View in: PubMed
    Score: 0.004
  149. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2003 Mar; 9(3):947-54.
    View in: PubMed
    Score: 0.004
  150. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol. 2002 Dec; 50(6):433-44.
    View in: PubMed
    Score: 0.004
  151. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 02; 196(5):619-28.
    View in: PubMed
    Score: 0.004
  152. Phase II trial of mitolactol in patients with metastatic melanoma. Cancer Treat Rep. 1982 Jan; 66(1):195-6.
    View in: PubMed
    Score: 0.003
  153. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
    View in: PubMed
    Score: 0.003
  154. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
    View in: PubMed
    Score: 0.003
  155. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
    View in: PubMed
    Score: 0.003
  156. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
    View in: PubMed
    Score: 0.003
  157. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001; 19(1):89-92.
    View in: PubMed
    Score: 0.003
  158. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther. 2000 Dec; 6(4):171-6.
    View in: PubMed
    Score: 0.003
  159. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol. 2000 Feb; 17(1):47-51.
    View in: PubMed
    Score: 0.003
  160. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.003
  161. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):581-9.
    View in: PubMed
    Score: 0.003
  162. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998 May; 16(5):1743-51.
    View in: PubMed
    Score: 0.003
  163. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997 Nov; 15(11):3399-407.
    View in: PubMed
    Score: 0.003
  164. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1997 Jun; 20(3):251-3.
    View in: PubMed
    Score: 0.002
  165. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol. 1996 Dec; 19(6):546-51.
    View in: PubMed
    Score: 0.002
  166. Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol. 1996 Nov; 19(6):433-42.
    View in: PubMed
    Score: 0.002
  167. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996 Jan; 2(1):29-36.
    View in: PubMed
    Score: 0.002
  168. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):134-9.
    View in: PubMed
    Score: 0.002
  169. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1993 Apr; 13(3):201-7.
    View in: PubMed
    Score: 0.002
  170. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Oct; 9(10):1806-10.
    View in: PubMed
    Score: 0.002
  171. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst. 1990 Dec 19; 82(24):1934-7.
    View in: PubMed
    Score: 0.002
  172. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Nat Immun Cell Growth Regul. 1990; 9(5):313-24.
    View in: PubMed
    Score: 0.001
  173. Human melanocytes cultured from nevi and melanomas. J Invest Dermatol. 1986 Jul; 87(1):95-101.
    View in: PubMed
    Score: 0.001
  174. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985 Apr; 45(4):1855-61.
    View in: PubMed
    Score: 0.001
  175. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep. 1984 May; 68(5):723-6.
    View in: PubMed
    Score: 0.001
  176. Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev. 1984 Mar; 11(1):1-26.
    View in: PubMed
    Score: 0.001
  177. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983 Nov; 9(5):689-96.
    View in: PubMed
    Score: 0.001
  178. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer. 1982 Jun 01; 49(11):2289-94.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.